Alongside Q1 results, Moderna (NASDAQ:MRNA) says the FDA has given the green light to begin the Phase 2 study on its novel coronavirus vaccine (mRNA-1273).
It’s expected to start imminently, with the goal of a Phase 3 study to begin in early summer, and approval as soon as 2021.
https://seekingalpha.com/news/3571075-moderna-cleared-for-phase-2-study-of-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.